Tipelukast

Small molecule

Phase 2topline reported

Evidence outlook

Type 2 Diabetes: topline reported 2026-09-28

The sponsor reported topline results on 2026-09-28 (Phase 2 MN-001-NATG-202 topline: Week 24 triglyceride and liver-fat changes not statistically significant vs placebo). The announcement is listed under Regulatory events.

Also in development:MASH / NASH · Phase 2Hypertriglyceridemia · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Hypertriglyceridemia
Other / comorbidity
NCT00295854 · MediciNova
2005-05 – 2006-10 · Interstitial Cystitis
What this study did

Competitive landscape

This drug's own stage for Hypertriglyceridemia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tipelukast: this drugPhase 2Small moleculeCysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenaseWeak signal
NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results.
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Olezarsen (Tryngolza)Phase 3RNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaReliable signal
NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083.
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signal
NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22).
Pravafenix
Phase 3(overall)
Small moleculeHMG-CoA reductase / PPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
Saroglitazar (Lipaglyn)
Phase 3(overall)
Small moleculePPAR-alpha/PPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
BW-00112Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
EDP167Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
MAR001Phase 2Monoclonal antibodyANGPTL4Weak signalFeatured results are safety only in this race
RBD5044Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SYH2070
Phase 2(overall)
RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
TLC-2716Phase 2Small moleculeLiver X receptor (LXR)not yet gradedNo reviewed efficacy summary in this indication
JMT202Phase 1/2Monoclonal antibodyβ-Klotho (KLB)not yet gradedNo reviewed efficacy summary in this indication
RN0361Phase 1/2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ALN-APOC3
Phase 1(overall)
RNA / oligonucleotideApolipoprotein C-III (APOC3)not yet gradedNo reviewed efficacy summary in this indication
ISH0688Phase 1Protein / enzyme therapeuticFGF21 receptornot yet gradedNo reviewed efficacy summary in this indication
Kylo-12Phase 1RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
VERVE-201Phase 1Gene therapy / editingANGPTL3 gene (hepatocyte genomic DNA)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tipelukast to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2026-12-31 · NCT05464784 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 September 2026Topline resultPhase 2 MN-001-NATG-202 topline: Week 24 triglyceride and liver-fat changes not statistically significant vs placebo
MediciNova, Inc. · Source ↗